319 related articles for article (PubMed ID: 27206263)
41. Ranibizumab Injection as Primary Treatment in Patients with Retinopathy of Prematurity: Anatomic Outcomes and Influencing Factors.
Huang Q; Zhang Q; Fei P; Xu Y; Lyu J; Ji X; Peng J; Li YA; Zhao P
Ophthalmology; 2017 Aug; 124(8):1156-1164. PubMed ID: 28412066
[TBL] [Abstract][Full Text] [Related]
42. Anti-Vascular Endothelial Growth Factor Therapy in Pregnancy: What We Know, What We Don't Know, and What We Don't Know We Don't Know.
Peracha ZH; Rosenfeld PJ
Retina; 2016 Aug; 36(8):1413-7. PubMed ID: 27388726
[No Abstract] [Full Text] [Related]
43. Are we there yet? Bevacizumab therapy for retinopathy of prematurity.
Darlow BA; Ells AL; Gilbert CE; Gole GA; Quinn GE
Arch Dis Child Fetal Neonatal Ed; 2013 Mar; 98(2):F170-4. PubMed ID: 22209748
[TBL] [Abstract][Full Text] [Related]
44. Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity.
Wu WC; Lien R; Liao PJ; Wang NK; Chen YP; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC
JAMA Ophthalmol; 2015 Apr; 133(4):391-7. PubMed ID: 25569026
[TBL] [Abstract][Full Text] [Related]
45. The efficacy and ocular safety following aflibercept, conbercept, ranibizumab, bevacizumab, and laser for retinopathy of prematurity: a systematic review and meta-analysis.
Chen J; Hao Q; Zhang J; Du Y; Chen H; Cheng X
Ital J Pediatr; 2023 Oct; 49(1):136. PubMed ID: 37814332
[TBL] [Abstract][Full Text] [Related]
46. Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in taiwan.
Wu WC; Yeh PT; Chen SN; Yang CM; Lai CC; Kuo HK
Ophthalmology; 2011 Jan; 118(1):176-83. PubMed ID: 20673589
[TBL] [Abstract][Full Text] [Related]
47. Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity.
Chung EJ; Kim JH; Ahn HS; Koh HJ
Graefes Arch Clin Exp Ophthalmol; 2007 Nov; 245(11):1727-30. PubMed ID: 17690897
[TBL] [Abstract][Full Text] [Related]
48. New trends in intravitreal anti-VEGF therapy for ROP.
Beccasio A; Mignini C; Caricato A; Iaccheri B; Di Cara G; Verrotti A; Cagini C
Eur J Ophthalmol; 2022 May; 32(3):1340-1351. PubMed ID: 35040348
[TBL] [Abstract][Full Text] [Related]
49. Timing of laser following intravitreal anti-vascular endothelial growth factor injections for aggressive posterior zone 1 retinopathy of prematurity.
Vinekar A
Indian J Ophthalmol; 2021 Aug; 69(8):1988-1989. PubMed ID: 34304161
[No Abstract] [Full Text] [Related]
50. Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between Ranibizumab and Bevacizumab.
Chen SN; Lian I; Hwang YC; Chen YH; Chang YC; Lee KH; Chuang CC; Wu WC
Retina; 2015 Apr; 35(4):667-74. PubMed ID: 25462435
[TBL] [Abstract][Full Text] [Related]
51. Post-Ranibizumab injection endophthalmitis in aggressive posterior retinopathy of prematurity.
Chandra P; Kumawat D; Tewari R; Azimeera S
Indian J Ophthalmol; 2019 Jun; 67(6):967-969. PubMed ID: 31124535
[TBL] [Abstract][Full Text] [Related]
52. Retinal detachment despite aggressive management of aggressive posterior retinopathy of prematurity.
Suk KK; Berrocal AM; Murray TG; Rich R; Major JC; Hess D; Johnson RA
J Pediatr Ophthalmol Strabismus; 2010 Dec; 47 Online():e1-4. PubMed ID: 21175113
[TBL] [Abstract][Full Text] [Related]
53. Refractive outcomes after intravitreal injection of antivascular endothelial growth factor versus laser photocoagulation for retinopathy of prematurity: a meta-analysis.
Kong Q; Ming WK; Mi XS
BMJ Open; 2021 Feb; 11(2):e042384. PubMed ID: 33568373
[TBL] [Abstract][Full Text] [Related]
54. Smouldering retinopathy of prematurity: a case treated by multiple antivascular endothelial growth factor therapy.
Balakrishnan D; Ambiya V; Jalali S; Rani PK
BMJ Case Rep; 2016 Aug; 2016():. PubMed ID: 27571916
[TBL] [Abstract][Full Text] [Related]
55. Outcomes after Intravitreal Bevacizumab versus Laser Photocoagulation for Retinopathy of Prematurity: A 5-Year Retrospective Analysis.
Hwang CK; Hubbard GB; Hutchinson AK; Lambert SR
Ophthalmology; 2015 May; 122(5):1008-15. PubMed ID: 25687024
[TBL] [Abstract][Full Text] [Related]
56. Very Late Reactivation of Retinopathy of Prematurity After Monotherapy With Intravitreal Bevacizumab.
Snyder LL; Garcia-Gonzalez JM; Shapiro MJ; Blair MP
Ophthalmic Surg Lasers Imaging Retina; 2016 Mar; 47(3):280-3. PubMed ID: 26985803
[TBL] [Abstract][Full Text] [Related]
57. Evaluation of Refractive Errors and Ocular Biometric Outcomes after Intravitreal Bevacizumab for Retinopathy of Prematurity.
Gunay M; Sekeroglu MA; Bardak H; Celik G; Esenulku CM; Hekimoglu E; Bardak Y
Strabismus; 2016 Jun; 24(2):84-8. PubMed ID: 27120579
[TBL] [Abstract][Full Text] [Related]
58. [Pharmacological treatment for retinopathy of prematurity].
Stahl A; Agostini H; Jandeck C; Lagrèze W
Ophthalmologe; 2011 Aug; 108(8):777-85; quiz 786-7. PubMed ID: 21853221
[TBL] [Abstract][Full Text] [Related]
59. Intraocular pressure effect of anti-vascular endothelial growth factor injection for aggressive posterior retinopathy of prematurity.
Ozdemir O; Arman A; Tayman C
Graefes Arch Clin Exp Ophthalmol; 2021 Nov; 259(11):3469-3476. PubMed ID: 34151383
[TBL] [Abstract][Full Text] [Related]
60. Time Course of Retinopathy of Prematurity Regression and Reactivation After Treatment with Ranibizumab or Laser in the RAINBOW Trial.
Fleck BW; Reynolds JD; Zhu Q; Lepore D; Marlow N; Stahl A; Li J; Weisberger A; Fielder AR;
Ophthalmol Retina; 2022 Jul; 6(7):628-637. PubMed ID: 35202890
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
